What is LQDA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 4.03B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for LQDA?

P/E (TTM) is 29.10 and 52-week range is $22.21 to $93.61 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s LQDA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for LQDA?

The company profile lists revenue (TTM) near $398M, net income (TTM) near $122M, EPS (TTM) near $1.39 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Liquidia Corporation based, and what identifiers does Chartloom list?

The company context section lists headquarters in Morrisville, North Carolina, US, 89.5M shares outstanding, ISIN US53635D2027 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Liquidia Corporation

$LQDA

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company is headquartered in Morrisville, North Carolina and currently employs 216 full-time employees. The company went IPO on 2018-07-26. The firm is engaged in the development and commercialization of therapeutic products for cardiopulmonary diseases. The firm operates within the biotechnology sector, focusing on treatments for conditions such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The firm operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enables precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is a PRINT‑engineered inhaled dry‑powder formulation of treprostinil designed to enhance deep lung delivery, improve therapeutic performance, and enable higher dose administration through a convenient inhaler.

Employees

216

Website

www.liquidia.com/

IPO

2018-07-26

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US53635D2027

Headquarters

Morrisville, North Carolina, US

Shares outstanding

89.5M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

80.40%

Browse other companiesFree AI scores and summaries for more stocks